FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,117 letters match. Newest first.

  1. Uriel Pharmacy, Inc.

    Uriel Pharmacy's homeopathic ampule drugs are unapproved new drugs and were made under serious CGMP violations.

    High risk
  2. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  3. Miers Laboratories, Ltd

    FDA warns Miers Laboratories over manufacturing violations and places import alert on its drugs.

    High risk
  4. Taizhou Kangping Medical Science and Technology Co., Ltd.

    FDA warns Taizhou Kangping about over-the-counter drugs labeled sterile that were not sterilized.

    High risk
  5. Compass Group USA

    FDA found Listeria in Compass Group's Fresh & Ready Foods plant, tied to an outbreak that sickened ten and killed one.

    High risk
  6. Apotex Inc.

    FDA cited Apotex's Richmond Hill sterile plant for failed investigations and aseptic contamination risks, prompting recalls.

    High risk
  7. Liebel-Flarsheim Company LLC

    Liebel-Flarsheim's Raleigh, NC sterile drug plant failed to investigate microbial and endotoxin test failures and let cleanrooms and equipment fall into disrepair.

    High risk
  8. Scientific Protein Laboratories, LLC

    FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.

    High risk
  9. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  10. The Tranzonic Companies/Innocore Sales & Marketing Inc.

    FDA says Innocore Sales & Marketing, an over-the-counter drug manufacturer, lacked finished-product, component, stability and quality-unit controls.

    High risk
  11. Qianjiang Kingphar Medical Material Co Ltd.

    FDA warned Chinese device maker Qianjiang Kingphar that dirty cleanrooms and weak environmental controls make its masks, dressings, wraps and drapes adulterated.

    High risk
  12. Contec Medical Systems Co., Ltd.

    FDA warns Chinese device maker Contec Medical Systems over quality system failures; its patient monitors and ultrasound devices face US border detention.

    High risk
  13. Royal Philips

    FDA warns Royal Philips over ultrasound device quality-system failures, including complaint handling and transducers distributed past useful life.

    High risk
  14. Acme United Corporation

    Acme United Corporation made antiseptic wipes with contaminated water and released sterile drugs without sterility testing.

    High risk
  15. Foshan Yiying Hygiene Products Co., Ltd.

    Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.

    High risk
  16. Guangxi Yulin Pharmaceutical Group Co. Ltd.

    FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.

    High risk
  17. BRS Analytical Services, LLC

    BRS Analytical Services, LLC made sterile OTC drugs in an unsuitable aseptic facility and recalled them over sterility assurance.

    High risk
  18. LEVO AG

    FDA says LEVO AG lacked a quality system, adverse-event reporting procedures, and device ID data for standup wheelchairs.

    High risk
  19. Allovate Therapeutics, LLC

    FDA warned Allovate that its Allerdent allergenic toothpaste is an unapproved drug and lacks a required biologic license.

    High risk
  20. Health and Natural Beauty USA Corp.

    FDA warns Health and Natural Beauty USA over CGMP failures and unapproved, misbranded SprinJene OTC toothpastes, including children’s products.

    High risk
  21. Technological Medical Advancements LLC

    Technological Medical Advancements LLC marketed Diowave laser systems for unapproved uses without required FDA clearance and had serious quality-system failures.

    High risk
  22. Naturich Cosmetique Labs

    FDA warned Naturich Cosmetique Labs over inadequate manufacturing controls for over-the-counter topical drugs, including contaminated water and untested ingredients.

    High risk
  23. Creative Essences, Inc.

    FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.

    High risk
  24. New Life Medical Services, LLC

    FDA says New Life Medical Services sells unapproved umbilical-cord, amniotic-fluid, and exosome products as drugs.

    High risk
  25. Dixon Investments Inc. dba ARI

    FDA cites Dixon Investments (ARI) for manufacturing-rule and unapproved/misbranded OTC aerosol drug violations.

    High risk
  26. Persōn & Covey, Inc.

    FDA cites Persōn & Covey for CGMP failures at its Glendale, CA drug plant and for selling unapproved Xerac AC and Drysol.

    High risk
  27. Time Challenger Labs International, Inc.

    Time Challenger Labs was warned for unapproved drug claims on five supplements and serious manufacturing violations.

    High risk
  28. Gracie's Kitchens, Inc.

    FDA warns Gracie's Kitchens over Listeria on RTE produce food-contact surfaces and sanitation failures.

    High risk
  29. Tan Nam Corporation

    FDA warned Tan Nam Corporation that its ready-to-eat soybean products were held under insanitary conditions and may be contaminated.

    High risk
  30. Hans Bakery Inc. d/b/a Andersen’s Bakery

    FDA found rodent and insect filth and serious food-safety failures at Hans Bakery's Hayward, CA facility making ready-to-eat bakery items and tuna salad.

    High risk
  31. Valentine Enterprises, Inc.

    FDA warned Valentine Enterprises that its dietary supplements were adulterated by manufacturing violations and misbranded by label errors.

    Medium
  32. Vidaslim Co.

    Vidaslim Co. dietary supplements are adulterated by CGMP failures and misbranded by label violations.

    Medium
  33. Media Networks Sydney Pty. Limited

    FDA says Australia's Media Networks Sydney failed to answer drug records requests for OTC Combantrin Chocolate Squares.

    High risk
  34. Chengdu Brilliant Biopharmaceutical Co., Ltd.

    FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.

    High risk
  35. The Richline Group, Inc.

    FDA warns Richline Group over unapproved Inverness ear care products and quality-system failures.

    High risk
  36. Janssen Vaccines Corp., A Johnson & Johnson Company

    FDA warned Janssen Vaccines over inadequate investigations of stopper complaints and missed regulatory notifications for its injection drug.

    Medium
  37. Columbia Cosmetics Manufacturing Inc.

    Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.

    High risk
  38. Yangzhou Yulou Paper Products Co., Ltd.

    FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.

    High risk
  39. Somerset Therapeutics Private Limited

    FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.

    High risk
  40. Mericon Industries, Inc.

    Mericon Industries sold Florical and Meribin supplements with unapproved drug claims for osteoporosis and serious manufacturing and labeling failures.

    High risk
  41. Hikal Limited

    FDA warned India's Hikal Limited that unresolved metal-particle complaints in its APIs and weak supplier oversight make its active ingredients adulterated.

    High risk
  42. Amneal Pharmaceuticals, LLC

    FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.

    High risk
  43. Wisconsin Pharmacal Company, LLC

    FDA warns Wisconsin Pharmacal over OTC drug manufacturing violations, including released rejected product and S. aureus contamination.

    High risk
  44. Chromatography Institute of America dba Compounder’s International Analytical Laboratory

    FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.

    High risk
  45. Synergy Animal Products, Inc.

    Synergy Animal Products marketed unapproved animal drugs for dairy cows with inadequate directions and major manufacturing violations.

    High risk
  46. Miach Orthopaedics

    FDA warns Miach Orthopaedics over quality-system failures in manufacturing its BEAR ACL Implant, including sterility monitoring and nonconforming product controls.

    High risk
  47. LeMaitre Vascular, Inc.

    LeMaitre Vascular's Artegraft graft plant in New Jersey drew an FDA warning letter for water, sterilization and recall-reporting failures.

    High risk
  48. Uscom Kft

    Uscom Kft marketed SpiroSonic AIR spirometer in the U.S. without FDA clearance and had multiple quality system failures at its Budapest plant.

    High risk
  49. Meds For Vets, LLC

    Meds For Vets compounded unapproved animal drugs from bulk substances and failed manufacturing quality rules, including sterility controls.

    High risk
  50. Anhui Hanbon Daily Chemical Co., Ltd.

    FDA warns Anhui Hanbon Daily Chemical over CGMP failures in OTC drugs, including use of an incorrect excipient and untested ingredients.

    High risk